Kymera has begun dosing in BREADTH, a global, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in approximately 264 adults with moderate to severe eosinophilic asthma. Over 12 weeks, the trial will assess three oral doses with change from baseline in FEV1 as the primary endpoint; secondary measures span safety, broader efficacy, and quality of life. Baseline enrichment requires eosinophils ≥300 cells/μL, FeNO ≥25 ppb, and pre-bronchodilator FEV1 40–80% predicted. Readout is slated for late 2027. In parallel, the BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis (AD) remains underway, with data expected by mid-2027.
The core development move is unambiguous: Kymera is running synchronized Phase 2b programs in asthma and AD to select dose and exposure targets for potential parallel Phase 3 registrational studies across Type 2 inflammatory indications. KT-621, an oral STAT6 degrader, is designed to intercept IL‑4/IL‑13 signaling downstream of receptor blockade. Phase 1 data in AD indicated deep STAT6 degradation and biomarker suppression with clinical signal across AD and comorbid allergic conditions, setting the rationale to test whether an oral degrader can deliver biologics-like activity in diseases dominated by injectables.
Strategically, this is an expansion play aimed at carving out space against entrenched IL pathway biologics by emphasizing convenience, class differentiation, and cross-indication leverage. Choosing a 12-week lung function endpoint suggests an efficiency-first screen to confirm dose-response and pharmacodynamic translation in the airway before committing to longer, costlier exacerbation studies that regulators typically require for approval. Running asthma and AD in parallel may compress dose optimization timelines and enable a single exposure paradigm across tissues, but it raises execution risk if pharmacodynamics diverge between skin and lung or if safety margins tighten with chronic systemic exposure.
For sites, the program is operationally attractive but selective. The 12-week duration, clear spirometry workflows, and common biomarker thresholds (eosinophils, FeNO) fit existing infrastructure, though FeNO capacity and centralized lab coordination will matter for screen pass rates. Competition for eosinophilic, moderate-to-severe asthma patients remains high given ongoing biologic trials, and enrichment criteria may narrow eligible pools further. Sites participating in both asthma and AD arms could benefit from shared staffing, screening funnels, and ePRO setups. CROs and vendors should anticipate tight integration of PD readouts, spirometry quality control, and adherence monitoring typical of daily oral regimens in respiratory studies.
For sponsors tracking regulatory expectations, the choice of FEV1 as the primary endpoint places the onus on demonstrating a clean dose-response and consistent biomarker modulation as a prelude to Phase 3 designs centered on exacerbation reduction and oral corticosteroid sparing. Safety will be scrutinized given the degrader modality and the breadth of STAT6 biology; regulators will look for durable, tissue-relevant PD, not just blood-based degradation. Payers will eventually benchmark against injectable standards on both outcomes and total cost of care, making head-to-head or contextually robust comparisons an eventual necessity.
The next set of signals will be whether the AD readout in mid-2027 and the asthma readout in late 2027 converge on a common dose with reproducible PD and clinical effect. Watch for early evidence of exacerbation trends, steroid-sparing potential, and any divergence in tolerability between indications. If Kymera can align dose, exposure, and PD across tissues, parallel Phase 3 execution becomes feasible; if not, the program could bifurcate, lengthening timelines. The competitive bar is high, and time to data is long, but a credible oral alternative in Type 2 disease would force a re-think of trial design, site workflows, and payer calculus across the category.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
